Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
One cent per share is one rusty coin on the ground somewhere per share, can Sanchez display an actual business operation of some sort to generate at least that much value in his company.
Tweet: “mdmpermian
@mdmpermian
·
Sep 8
Field Update: $MDMP has started shipping oil from the Brown #1. Transoil has picked up the first load, 2 more scheduled to go this month. #MDMP“
With looming Rail shutdown, energy suppliers and their potential reserves would likely be needed more than ever. Scouts from big companies might pay a big premium for an existing operation in this time frame, the company could leverage the rail shutdown to get a good price for shareholders in any sale of company to Exxon, Gulf, BP, for example.
IV=Invent Ventures
922
9 ‘22
September 2022
Can only wait for the 200 SMA to turn downward now as the 9/2/22 chart opportunity didn’t result in timely follow through, on 11/3/21 the gap at .0701 occurred, looks like that is the next price before something good occurs, the one year consolidation completes on 12/29/22 as a possible day to check back.
Next chance mid October imo, the 13th
Looks like it was correct to wait for second half of September, October 4 is the completion of 6 month consolidation, price target should be 27.00 on cup and handle completion, with such a way to go to get to 27.00 anything could happen at anytime should be interesting at least imo
If the deal happens quickly the gaps won’t matter, speculative
Matrix code:
21 Vianet
21 (22-9-1) 14 5 20
Could indicate that the end location or final Shareprice for the purchase of the company will be $14.00.
Alternative code:
U (22-9-1) Net
Backwards:
10.00 1-9-22 U
“12:22a ET 9/14/2022 - Dow Jones
VNET Founder's Privatization Offer Looks Serious -- Market Talk
0419 GMT - VNET Group founder Josh Chen's latest offer to take the Chinese data-center operator looks serious to Jefferies analysts, who think he will likely follow through. They say in a note that the founder has likely already lined up financing, adding that the move looks justified given that VNET is significantly undervalued by the U.S. market. Jefferies reckons that the offer price of US$8.20 per ADR may need to be raised, as it looks quite low compared to peers. But it doesn't expect a bidding war, given the lack of other serious, viable potential buyers. (yifan.wang@wsj.com)
(END) Dow Jones Newswires
September 14, 2022 00:22 ET (04:22 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.“
Great work by new CFO, instant energy into company, chart looks like a classic surge pattern
https://www.otcmarkets.com/otcapi/company/financial-report/346353/content
Sanchez butt fumble or touchdown?
Can really surge here with volume, low float
Expecting major deal hopefully big tech takes notice of Dish deal…
It can get back to 1.00 imo near term, keep making deals and progress
They appear to have more than enough cash to sustain until major profits occur, business being managed well, good long term investment from here imo.
Numbers look good, no gaps:
“4:30p ET 9/13/2022 - BusinessWire
Cenntro Electric Group Announces First Half 2022 Unaudited Financial Results
--1H22 number of vehicles sold increased 23% year on year
--Management to Host Conference Call on Tuesday, September 13 at 5:30 p.m. ET
Cenntro Electric Group Limited (NASDAQ: CENN) ("Cenntro" or "the Company"), a leading EV technology company with advanced, market- validated electric commercial vehicles ("ECVs"), today announced its financial results for the first half year ended June 30, 2022.
First Half 2022 Operational and Financial Highlights
The number of commercial vehicles sold was 337 units, an increase of 23% from 273 units sold in the same period of 2021.Net revenue was $5.0 million, an increase of 105% from $2.5 million in the same period of 2021.Cash and cash equivalents were $183.0 million as of June 30, 2022, compared with $2.0 million as of June 30, 2021.
"During the first half of 2022, we continued to execute on our strategic initiatives and grow our topline despite a challenging macroeconomic environment. Sales volume of our electric commercial vehicles reached 337 units, representing an increase of 23% year-over-year. Out of that, we sold 132 units of our newly launched Logistar 200 (the "LS 200") model, which doubled our average selling price. This demonstrates our capabilities for executing our tiered product strategy while addressing various customer demands amidst global uncertainty," said Peter Wang, Chief Executive Officer.
Mr. Wang continued, "We also made progress across multiple fronts during the first half of 2022. First, we introduced three new EV products, the Logistar 100 (the "LS 100"), Logistar 260 (the "LS 260") for the European market and Logistar 400 (the "LS 400") for the North American market. We have already begun receiving pre-orders for these new products. These new vehicles come with higher price points and will continue to improve our product mix. Second, we made the strategic decision to bring advanced battery technology and production in-house, which will strengthen our supply chain. Third, we started new vehicle assembly in the U.S. and Europe as well as began building out our EV distribution and services infrastructure. These initiatives set a strong foundation to accelerate our growth. Going forward, we believe our expanded product lineup and leading technology will position us well to capture tremendous growth opportunities in the transformation of the global commercial fleet industry to zero-emission vehicles."
Edmond Cheng, Chief Financial Officer, added, "Increased vehicle sales and improved product mix helped us achieve 105% year-over-year revenue growth for the first six months of 2022. These results reflect our continuous investment in product development and partnership with the right OEMs to enhance our product offerings to meet market demand. We have also stepped up our investment in sales and marketing, infrastructure, and research & development to support our growth objectives. However, in light of the uncertain macroeconomic environment, we will remain cautious in managing our expenditures and working capital in order to preserve a strong balance sheet."
Recent Developments & First Half 2022 Business Highlights
New Vehicle Development: EPA certification for LS 400 is expected by end of September 2022 while its pilot production has started; LS 100 rolled off from production lines and received EU Type Approval; LS 260 received EU type approval and production has commenced.The LS 400 is designed primarily for urban delivery and services to cover two significant markets that include last mile delivery and vocational fleets and upfitters. The Company has showcased the LS 400 series at various key industry events and exhibitions that have led to significant interest.Cenntro's first LS 100 rolled off the production line with deliveries to Europe scheduled in the mid September with launches in the Asian, Caribbean, and South American markets to follow. The LS 100 is a versatile, compact light cargo van purpose-built to serve diverse commercial applications, especially in urban areas with high population density.The LS 260 is a new addition to the Logistar series. This new vehicle will be targeted toward a wide range of applications in the trades, couriers, express and parcel services, logistics solutions, and facility management segments, with initial deliveries to Europe scheduled in September.
The Company has opened the order books for LS100, LS 260 and LS 400 models.
Launch of Lithium Battery Project: The construction of the battery factory building was completed, and internal renovation has been progressing; Proprietary production machinery has already been tested and validated; Filing for three patents.Given the backdrop of increased battery costs and global supply chain challenges, Cenntro set up a unit, Cennatic Power Inc., to produce advanced lithium-ion batteries for its ECVs to secure and stabilize its battery supply. Bringing production of essential battery technologies and manufacturing process in-house will enable the Company to expedite the development of ECVs, reduce supply chain dependency on China, and lower battery cell costs.Launch of Vehicle Assembly in U.S. and Europe: The European assembly factory in Germany is fully functional; Pilot assembly scaled in the New Jersey facility; Florida assembly capability will be ready soon.The additional vehicle assembly in the U.S. and Europe will boost the Company's total manufacturing or assembly plants to five. Assembly strategy and capacity is on track to serve growing demands for its ECVs.Building Vehicle Distribution and Service Infrastructure: Establishing EV centers with focus on the U.S. and European markets; Developing and setting up parts distribution warehouses; Signing up distributors/dealers/value-added resellers.Cenntro is also establishing EV centers across the U.S., Poland, Germany, Spain, Morocco and Jamaica to align with its go-to-market strategy for new growth.Cenntro has initiated the transition from private label distribution to a direct B2B marketing and sales team in North America. The Company will assemble its Metro product in-house and market Metro directly to its distributors in the U.S. Cenntro has ended its channel distribution partnerships in the U.S. and will now have full control over the production and sales in order to assure product quality, reduce the overhead and boost brand awareness.
First Half 2022 Financial Results
Net Revenues
Net revenue was $5.0 million in the first half of 2022, an increase of 105% from $2.5 million in the first half of 2021. The increase was due to both a 23% growth in sales volume as well as an improvement of the average selling price ("ASP") from $7,354 in primarily selling Metro Car Kits last year to $14,400 in the improved product mix to include 132 units of the LS 200 at a much higher ASP.
Gross profit
Gross profit was $0.53 million in the first half of 2022, an increase of 18% from $0.45 million in the first half of 2021. Gross margin was 10.6% in the first half of 2022, compared with 18.3% in the first half of 2021. The change in gross margin was primarily due to both the inflation pressure on input costs such as battery and the shipping costs, especially as shipping costs of a 40-foot container to Hamburg or New York have risen to a high of $20,000 for the first half of 2022 from the average of $2,000 for the same period last year. Recently in August, the average cost of shipping the same 40-foot container has come down to $5,000.
Operating expenses
Total operating expenses were $24.7 million in the first half of 2022, compared with $5.0 million in the first half of 2021. The increase was primarily driven by headcount growth and higher legal and compliance costs to support our growth as a public company. In addition, in the first half of 2022, we also incurred non-recurring fees and expenses of approximately $6.5 million related to the compensation to certain directors for their past services to the Company and a non-recurring expense of approximately $1.8 million for compensation in 2022 related to FOH divestiture. Excluding these one-time costs, our operating expenses in the first half of 2022 would have been $16.4 million.
Net income (loss)
Net loss was $23.1 million in the first half of 2022, compared with net loss of $4.5 million in the first half of 2021.
Adjusted EBITDA(1)
Adjusted EBITDA was negative $12.9 million in the first half of 2022, compared with Adjusted EBITDA of negative $3.0 million in the first half of 2021.
Cash and cash equivalents balances
Cash and cash equivalents were $183.0 million as of June 30, 2022, compared with $2.0 million as of June 30, 2021.
First Half 2022 Results Conference Call
Cenntro Electric Group CEO Peter Wang, and CFO Edmond Cheng will host a conference call followed by a question-and-answer session on Tuesday, September 13, 2022 at 5:30 p.m. Eastern time to discuss its financial results for the six-month period ended June 30, 2022.
Please register in advance of the conference call using the link provided below. Conference access information will be provided upon registration. Participant Online Registration: https://s1.c-conf.com/diamondpass/10025106-fmsn3a1.html
The conference call will be broadcast live and available for replay at https://edge.media-server.com/mmc/p/qrrriixa and via the investor relations section of the Company's website at ir.cenntroauto.com. A replay of the conference call will be available after 9:30 p.m. Eastern time through September 21, 2022.”
Big news possible within 10 calendar days chart opportunity predicts
No gap exists actually, the .15 was filled, churning higher it seems
This could be the catalyst the chart says will take to .28
.20 on tangible progress
On the day it spiked it opened at .0320 not .03, the previous close, hence the gap. Investors see this stock as a low volume safe haven with upside potential imo which is why it hasn’t filled the gap yet, investors want to see why they extinguished their debt. I don’t care who takes me seriously, I am here to show how correct I am in my theories.
“Tuesday, 08/23/2022 10:00:53 AM
October 1 the 6 month consolidation completes, May coincide with congressional action on legalization before elections.
”
Current Market cap 42 million while working on NASA space launches, SpaceX launches
-6%
“B. Please list any subsidiaries, parents, or affiliated companies.
Aster Brands, Inc.
Subsidiary
C. Describe the issuers’ principal products or services.
Management intends on folding in select components of its existing financial technology ecosystem, including established and to be formed entities, along with their respective lines of business, into the Company. The intended result is for the Company to be the fully reporting survivor to the Aeon financial technology ecosystem, and its corresponding lines of business.“
“ NOTE 1 - NATURE OF OPERATIONS AND REVERSE ACQUISITION TRANSACTION (a) TheCompany.
Management intends on folding in select components of its existing financial technology ecosystem, including established and to be formed entities, along with their respective lines of business, into the Company. The intended result is for the Company to be the fully reporting survivor to the Aeon financial technology ecosystem, and its corresponding lines of business.
Further, Management intends on utilizing the Company as a vehicle for investing in and accelerating the growth of a select portfolio of groups of companies that are in synergistic sectors and industries.”
https://www.otcmarkets.com/otcapi/company/financial-report/342186/content
Share Structure
Market Cap Market Cap
9,036,150
09/12/2022
Authorized Shares
100,000,000
09/12/2022
Outstanding Shares
50,509,501
09/12/2022
Restricted
42,476,031
09/12/2022
Unrestricted
8,033,470
09/12/2022
Held at DTC
4,779,683
09/12/2022
Float
8,033,470
03/15/2015
Par Value
0.001
IDEA
Invent Ventures, Inc.
Pink Current Information
Verified Profile Profile 08/2022
Transfer Agent Verified
SIDU closed below the lower bollinger band on the 5 minute chart 11 times so far today without reversing higher, and the 5 day consolidation completed an hour into the trading session, 4 hours ago, the market is treating this company like it has no value when it is working with NASA and SpaceX and many other companies.
When a stock closes below the lower bollinger band on the one month chart and then reverses as it enters back within the bollinger bands, it is supposed to then head toward the upper bollinger band and close above it prior to any reversal lower, if the company outlook is good, SIDU appears to have a good long term outlook, and closed below the lower bollinger band on 8/22 and 8/23 and then properly reversed higher but never yet has closed above the upper bollinger band. SIDU’s spike on September 7 closed below the upper bollinger band, why does it appear as if that was a Reversal point lower? The market is not functioning properly in this specific instance imo, and is therefore disrespecting this shareprice while adding volume to other companies that do not deserve any investment at all based on the failed or non-existent products/services and mismanagement of those other companies with 10x volume today in comparison to SIDU, billionaire investors allow companies which by all measures are doing everything correctly to have Shareprices disrespected on a daily basis especially when those investors are working with the disrespected company directly and also as a matter of principle.
Price comparison:
BBIG - 1.16 a share OS 233 million - no tangible product, company c-suite in chaos
Todays volume 16 million.
SIDU - 2.44 a share OS 19 - 30 million - partnerships with NASA, SpaceX etc
Today’s volume 430,000.
Conclusion: the market needs to properly value companies and investors should invest imo in companies that at minimum have a product or service. In general, the US economy needs leadership from billionaires who should be more vocal in their investments in companies that have a tangible product or service in order to teach investors how to allocate money properly. The comparison above imo represents a complete inversion of economic reality and a flawed market of Mia allocated capital when considering the specific circumstances of BBIG and SIDU, how is it possible that the volume is inverted in that way.
Setting aside all the other partnerships (SpaceX etc) and future potential, When the major NASA subcontractorship was announced the company jumped from 1.44 a share to its current price 2.44 a share, there are 16 million - 30 million outstanding shares depending on the selling shareholder and all that, meaning that if the NASA deal was its only deal then the market would be currently valuing the NASA subcontractor remember on a deal worth billions at only 30 million dollars revenue annually ($1 per share).
“9:00a ET 7/21/2022 - BusinessWire
Sidus Space Fabricates Hardware in support of NASA's Artemis Program and their Space Launch System (SLS) Manned Vehicle
Sidus Space, Inc. (NASDAQ:SIDU), a Space-as-a-Service company focused on mission critical hardware manufacturing; multi-disciplinary engineering services; satellite design, production, launch planning, mission operations; and in-orbit support, is proud to announce that it has completed the fabrication of the first set of hardware in support of NASA's Artemis Program and their Space Launch System (SLS) Manned Vehicle.
As a subcontractor, Sidus is responsible for the build, qualification, and testing of Umbilical Quick Disconnects for the Environmental Control System (ECS) on the Universal Stage Adapter (USA) for NASA's Space Launch System (SLS). The fabrication of the first set of hardware was completed to support umbilical testing at Jacob's Launch Equipment Test Facility (LETF) at Kennedy Space Center and was delivered last week. NASA reviewed and approved the hardware earlier this month.
Dynetics, a wholly-owned subsidiary of Leidos (NYSE: LDOS), is the prime contractor building the Universal Stage Adapter (USA) for NASA's Space Launch System (SLS). The SLS is a super heavy-lift launch vehicle that provides the foundation for human exploration beyond Earth's orbit. With its unprecedented power and capabilities, SLS is the only rocket that can send Orion, astronauts, and cargo directly to the Moon on a single mission. The SLS is designed to be flexible and evolvable for deep-space destinations.
Sidus Space has supported multiple major space programs such as Orion, Space Launch System (SLS), Centaur, Mobile Pad/Mobile Launcher, International Space Station, and Dream Chaser. In the future Sidus has already been selected to support the Exploration Extravehicular Activity Services (xEVAS).
Carol Craig, Sidus Space CEO said, "Month after month we deliver mission critical hardware to a variety of commercial and government customers. Sidus Space has been manufacturing, assembling and testing hardware for over ten years. We have been supporting several of our customers for many years and are seeing an increase in orders. Our manufacturing capability is how Sidus Space got started and is still today an important revenue stream that helps define our overall Space-as-a-Service offering."”
“12:24p ET 7/19/2022 - Benzinga
Why Shares Of Sidu Space Are Blasting Off
Sidus Space (NASDAQ: SIDU) shares are trading higher after the company expanded its relationship with Teledyne Technologies. The company will now manufacture components for Teledyne Marine's Massachusetts facility.”
“10:03a ET 6/16/2022 - Dow Jones
Sidus Space Shares Continue to Skyrocket After NASA Pact
Shares of Sidus Space Inc. gained 64% to $7.65 in early trading Thursday, continuing the previous day's ascent on news the company will be a major subcontractor for the National Aeronautics and Space Administration's Exploration Extravehicular Activity services contract.
Trading was paused twice early in the session due to volatility.
The space-as-a-service company said Wednesday that it was selected to join the Collins Aerospace team, itself a unit of Raytheon Technologies Corp., that was awarded the NASA contract.
Sidus said it will be a major subcontractor on the Collins team through the life cycle of the Exploration Extravehicular Activity Services program. “
“1:40p ET 6/15/2022 - Dow Jones
Sidus Space Up 81% as Company Will Be Subcontractor on NASA Pact
Sidus Space Inc. shares rose 81% to $2.61 as the company said it will be a major subcontractor for the National Aeronautics and Space Administration's Exploration Extravehicular Activity services contract.
Sidus is part of the Collins Aerospace team. Collins is a unit of Raytheon Technologies Corp.
NASA said on June 1 that the contract focused on spacesuits and spacewalk systems, awarded to Axiom Space Inc. and Collins, could be worth $3.5 billion over 12 years.”
291.6 million a year / 30 million a year to SIDU, a major subcontractor is 9.72 percent of the awarded contract money going to SIDU as the market currently would be valuing it if that were SIDU’s only deal. Since it isn’t SIDU’s only deal, then the market is probably valuing the award at 15 million a year or 5% of the total awarded money. Ok fine, but these companies should trade at a forward multiple especially once they become nationally recognized and are working with major companies and government agencies. The multiple here appears to be non-existent.
Furthermore, any stock below 5 dollars is considered a penny stock by many in the investing industry, it would be better perceived in my opinion for both NASA and SpaceX if the shareprice of SIDU had a grown-up Shareprice since those companies are relying on SIDU and the more money SIDU has the more success can occur in launching rockets, that goes for any company NASA or SpaceX or even Apple deal with, instead of hoarding as much money as possible and denying money to those you rely on, if everyone on the team is stronger financially then that is the best long term strategy if success is the goal.
News soon could cause a spike to .28 closing price as per chart, might be why the shares were registered for sale imo, highly speculative
Pump the oil and sell the oil
“9:09a ET 9/12/2022 - Benzinga
DISH Media Partners With SeaChange And Beachfront To Launch National Linear Programmatic
First-of-its-Kind Real-Time Ad Sales Optimization
Providing advertisers flexible ad-buying across 7+ million households
Viant is the first Demand-side Platform (DSP) to utilize this new technology
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- DISH Media (NASDAQ:DISH) announced a first-of-its-kind solution enabling advertisers to access premium linear TV inventory through a real-time, programmatic buying model. The solution, National Linear Programmatic (NLP), will work across DISH TV's 7+ million households nationwide. NLP is enabled by Beachfront, the sell-side ad server built for convergent TV, and SeaChange International, Inc. (NASDAQ:SEAC), a leading provider of video delivery and ad insertion platforms.
"Pioneering this new capability is another step in our effort to build more open and interoperable solutions for our advertisers," said Kevin Arrix, senior vice president, DISH Media. "The television marketplace is evolving, and providing our valuable linear TV inventory via programmatic technology is another positive step in this direction."
NLP will enhance DISH Media's existing sales channels while presenting the demand-side with a more flexible, interoperable ad-buying solution, allowing marketers to buy in a more practical, scalable and efficient way. Benefits include:
Ability to expose linear inventory to be executed in real-time
Fully automated buy process for linear demand partners
Ability for demand-side to plan linear alongside their digital/over-the-top buys for a more holistic view and more control of their linear exposure
Provides a greater range of buyers access to linear TV
"Enabling new and incremental advertising capabilities for DISH TV with our Advanced Advertising Platform is a true milestone in our quest to optimize ad yield for operators globally. Adopting the principles of addressability and automation from the digital landscape to enable real-time auctions for linear TV through industry-standard digital advertising marketplaces is a gamechanger and a growth milestone for the industry," said Chris Klimmer, president, SeaChange. "Together with Beachfront, we will continue our mission to optimize ad yield for operators by attracting additional advertisers, enabling real-time bidding and automating ad sales."
"Having DISH TV deploy an automated solution is truly going to accelerate the growth of programmatic capabilities in the industry, particularly for TV media buyers, programmers and distributors," said Chris Maccaro, chief executive officer, Beachfront. "Advertisers are constantly looking for the fastest, most efficient use of time and money. Having access to DISH TV's national linear TV inventory with the tools required to get a campaign live in a day will provide a lot of new flexibility."
"This exciting new offering is a great option for digital-first buyers who want to expand their reach and take advantage of DISH's linear footprint," said Jonathan Ahuna, senior vice president of operations, Viant. "It delivers a one-two combination of being able to buy ads seconds before the ads' airing, then, through the power of Viant's Adelphic DSP, quickly report out on the buy, vastly reducing the traditional delay of linear reporting."
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”
“4:05p ET 9/12/2022 - Globe Newswire
SeaChange Reports Fiscal 2Q 2023 Financial and Operational Results
EQNX::TICKER_START (NASDAQ:SEAC), EQNX::TICKER_END -- Revenue of $7.3M for Fiscal 2Q 2023 was up 12% y/y and 9% sequentially
-- Gross Margin up 200 basis points y/y to 65% with execution on profitable growth
-- Attractive outlook with focus on streaming, digital advertising, and Connected TV
SeaChange International, Inc. (NASDAQ: SEAC), ("SeaChange" or the "Company") a leading provider of video delivery, advertising, streaming platforms, and emerging FAST (Free Ad-Supported Streaming TV services) development, today, reported financial and operational results for the fiscal second quarter ended July 31, 2022.
Fiscal Second Quarter 2023 and Recent Highlights
Management Commentary
"We have made great progress in the first half of fiscal 2023 in advancing our pursuit to becoming a leading technology provider that enables video distribution and monetization, while also generating improved financial results," said SeaChange's Chairman and Chief Executive Officer Peter D. Aquino. "We are continuing to grow our existing customer engagements, while expanding our services and offerings with new logos in high growth international markets that offer SaaS-based recurring revenue streams. We are leveraging our expertise in software engineering related to video and ad insertion services on Connected TVs and streaming devices. Additionally, we are encouraged by our continued revenue growth and positive non-GAAP operating income, which solidifies our platform for further market expansion through organic growth, and potential strategic alternatives to gain scale."
Fiscal Second Quarter 2023 Financial Results
-- Ended the second quarter of fiscal 2023 with cash and cash equivalents of $14.3 million and no debt.”
The PR headline is a false implication:
“4:13a ET 9/10/2022 - Globe Newswire
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody(R) ADG126 in Patients with Advanced Tumors”
Yes technically a couple of patients had anti-tumor activity, but the headline can easily be misconstrued and read at first glance to infer that all patients had that positive reaction. The headline should be clear, naming the exact number of patients who experienced tumor reduction out of the total number of patients, if they want to claim that a build up of ADG in the tumors is anti-tumor activity then that is different “activity” than tumor reduction, if I paint mayonnaise every day on non-reducing tumors of a patient over the course of 6 months, mayonnaise would also safely show up in trial results accumulating in the area.
Company is trying to use manipulative language to pass their overall failure, so far, off as success, calling the results “intriguing”, “anti-tumor activity” implying falsely that it was across all patients, as if all the patients had anti-tumor activity when that isn’t what is reported below that verbiage in the PR, gotta critically read the PR to see how they wrote it,
Deceiving PR imo, prime example, this statement falsely implies that all patients hand this positive reaction while also being “technically true” so as not to be called out for the implication,‘can you detect the deceptive language ?
"ADG126 continues to demonstrate a remarkable safety profile, highly differentiated from both the currently approved anti-CTLA-4 therapy and others in development, as well as antitumor activity in heavily pre-treated patients with cold tumors,"
“4:13a ET 9/10/2022 - Globe Newswire
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody(R) ADG126 in Patients with Advanced Tumors
EQNX::TICKER_START (NasdaqGM:ADAG), EQNX::TICKER_END - Best-in-class profile demonstrated with repeat dosing across dose levels -
- Antitumor activity observed in cold tumors with steady accumulation of activated ADG126 -
- On track in 2022 to report results of ADG126 dose escalation in combination with anti-PD-1 therapy, establishing dose regimen for phase 2a dose expansion cohorts -
Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced the publication of data showing the best-in-class potential of ADG126, a masked, anti-CTLA-4 SAFEbody(R). Interim results from the Phase 1 portion of an ongoing Phase 1b/2 trial of ADG126 are being presented at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris, September 9 - 13, 2022.
The poster, titled "Phase 1 Results Demonstrate Highly Differentiated Safety and PK Profile of ADG126, a Masked anti-CTLA-4 SAFEbody(R) in Patients with Advanced Solid Tumors," reviewed data from the first-in-human, open label, phase 1 dose-escalation and dose expansion. The poster reports data on 26 patients with advanced metastatic solid tumors, the majority (58%) of whom received three or more lines of prior therapies and nearly half (42%) of whom progressed from prior immuno-oncology (IO) therapy.
Key findings include:
-- Safety: ADG126 monotherapy showed an unprecedented clinical safety profile at dosing levels up to 20 mg/kg when administered to this heavily pretreated patient population once every three weeks. ADG126 was well tolerated, with no dose-limiting toxicities or treatment-related Grade 3 or higher adverse events observed. The most frequent treatment related adverse events (TRAEs) (greater-than or equal to10%) were fatigue (12%), pruritis (12%), rash (12%) and diarrhea (12%). Dose escalation is completed at 20 mg/kg and dose expansion is ongoing at 10 mg/kg.
-- Antitumor Activity in Cold Tumors: With 18 cycles of treatment at 1 mg/kg, an ovarian cancer patient experienced significant, continued reduction of an established ovarian cancer biomarker, CA125, dropping 90% to within the normal range for full clinical benefit. As of cycle 16, the patient experienced a 22% decrease in target lesions. Previously, this patient had surgery and five prior lines of systemic therapies. At the data cut-off of August 17, 2022, the disease control rate was 39% (9/23 evaluable patients).
-- Pharmacokinetics: ADG126 plasma pharmacokinetics (PK) were approximately linear and activated ADG126 accumulated steadily during repeat dosing across different dose levels. This suggests prolonged exposures of activated ADG126 in the tumor microenvironment (TME), with cleaved ADG126 on average accumulating greater-than or equal to3-fold during repeat dosing, resulting from an approximately 1.5-fold longer half-life of total ADG126 compared with its parental antibody.
"ADG126 continues to demonstrate a remarkable safety profile, highly differentiated from both the currently approved anti-CTLA-4 therapy and others in development, as well as antitumor activity in heavily pre-treated patients with cold tumors," said Dr. Gary Richardson, OAM, MBBS, FRACP, Group Director at Cabrini Health Research, Neil Beauglehall Endowed Chair, Medical Oncology Research, and Professor of Medicine at Monash University, Australia, said, "An intriguing case study of our poster is the experience of a patient with ovarian cancer, whose tumor reduced by 22 percent accompanied by normalization of an established clinical biomarker, CA125, dropping by tenfold after more than one year of treatment with ADG126 administered every three weeks at only 1 mg/kg. These data clearly demonstrate the monotherapy activity of this novel antibody, ADG126, supporting its ongoing evaluation as both monotherapy and in combination with anti-PD-1 agents."
Trials evaluating the combination of ADG126 and anti-PD-1 therapies are ongoing in patients with advanced, metastatic tumors in the US, China and Asia Pacific (APAC), evaluating optimized doses of ADG126 in targeted tumors.
ADG126 SAFEbody applies precision-masking technology to the parental anti-CTLA-4 antibody, ADG116, for conditional activation in the TME to expand the therapeutic index and further address safety concerns with existing CTLA-4 therapies. Binding to the same unique epitope as ADG116, the masked ADG126 is designed to provide enhanced safety and efficacy profiles due to the combination of the potent Treg depletion in the TME and partial ligand blocking by the activated ADG126, which is accumulated steadily for the prolonged tumor killing effect in TME.”
Results not good: 2 out of 26 success rate
“ -- Antitumor Activity in Cold Tumors: With 18 cycles of treatment at 1 mg/kg, an ovarian cancer patient experienced significant, continued reduction of an established ovarian cancer biomarker, CA125, dropping 90% to within the normal range for full clinical benefit. As of cycle 16, the patient experienced a 22% decrease in target lesions. Previously, this patient had surgery and five prior lines of systemic therapies. At the data cut-off of August 17, 2022, the disease control rate was 39% (9/23 evaluable patients).”
Lipstick on a pig (poster), so far. While it is great that one person got better and safety profile was great, A 1/26 success rate (what they call their case study) isn’t good enough imo. From March until August 17 the disease was controlled in 9/23 patients, not good enough yet imo with only one or two reductions in tumors out of all the dosed patients.
Todays PR is a repeat of the August 30 PR, word for word, except that it was on a poster at a conference:
“ -- Compelling clinical safety demonstrated at unprecedented dosing levels with repeat dosing: -- Completed monotherapy dose escalation of ADG126 in 19 patients up to 20 mg/kg administered every three weeks with repeat dosing, and continued to enroll patients in dose expansion at 10 mg/kg. -- ADG126 monotherapy was well tolerated with no dose-limiting toxicities or treatment-related serious adverse events observed following repeat dosing across all dose levels, as reported in an abstract at the 2022 American Society of Clinical Oncology annual meeting. -- Clinical evaluation with anti-PD-1 therapies is ongoing to establish the dose and schedule for phase 2 combination cohorts. In combination cohorts with toripalimab, the safety review committee has cleared the 6 mg/kg dose administered every three weeks, approved dose expansion at 6 mg/kg, and recommended further dose escalation to 10 mg/kg, the highest dose level ever reported for the combination of anti-CTLA-4 and anti-PD-1 therapies. -- Encouraging antitumor activity observed as monotherapy in cold tumors: -- In a cohort of heavily pre-treated patients, ADG126 monotherapy resulted in durable reductions in target lesions over 20% in two patients with cold tumors: -- One ovarian cancer patient who experienced significant, continued reduction of an established ovarian cancer biomarker, CA125, dropping 90% to within the normal range for full clinical benefit after receiving up to 18 cycles of treatment at 1 mg/kg, as of this release. -- One uveal melanoma patient who received prior immuno-oncology treatment, having progressed after the combination of nivolumab and ipilimumab. -- Updated interim results will be presented in a poster on September 12 at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris, September 9 -- 13, 2022 -- Both monotherapy and combination trials continue to enroll patients with advanced, metastatic tumors in the US, China and APAC, evaluating optimized doses of ADG126 in targeted tumors. -- Pharmacokinetics show effectiveness of precision masking technology: -- In monotherapy evaluation, ADG126 plasma pharmacokinetics (PK) were approximately linear and activated ADG126 accumulated steadily during repeat dosing across different dose levels. -- This reflects prolonged exposures of activated ADG126 in the tumor microenvironment (TME), with cleaved ADG126 in plasma on average accumulating >2-fold during repeat dosing. ”
-Dow Jones Newswires
August 30, 2022 17:25 ET (21:25 GMT)
Two weeks till opportunity here 9/25, maybe they can make some headway to paying off their debts with this political season coming up
Pump and the dump this week, remember that story from the dark knight rises about the Ruby thief, Bhat had a surge recently on questionable reasoning, could be same crew money laundering on a Batman theme.